Anixa Biosciences to Present FSHR-Targeted CAR-T Phase 1 Data in Puerto Rico
Anixa Biosciences will present Phase 1 clinical data on lira-cel, its FSHR-targeted CAR-T therapy for recurrent ovarian cancer, at the SGO Annual Meeting in San Juan, Puerto Rico, April 10–13, 2026. Dr. Robert Wenham of Moffitt Cancer Center will detail the trial design, objectives and current enrollment status.
1. SGO Annual Meeting Presentation
Anixa Biosciences will update its shareholders and the oncology community on the ongoing Phase 1 lira-cel trial at the SGO Annual Meeting in San Juan, Puerto Rico, from April 10 to 13, 2026. Dr. Robert Wenham, Chair of Gynecologic Oncology at Moffitt Cancer Center and principal investigator, will present the study title, objectives and interim status.
2. Phase 1 Lira-cel Trial Overview
The trial (ClinicalTrials.gov NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies. Key endpoints include safety, tolerability and preliminary efficacy in patients with tumors expressing the follicle-stimulating hormone receptor (FSHR).
3. CAR-T Mechanism and Technology
Lira-cel employs chimeric endocrine receptor-T cell (CER-T) technology, using the natural FSH ligand to bind FSHR selectively on ovarian tumor cells while sparing healthy tissue. This collaboration with Moffitt Cancer Center differentiates it from antibody-based CAR-T approaches and targets a receptor uniquely expressed in ovarian cancer.